Review

cmc2.23 (ChemMaster International)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ChemMaster International cmc2.23

( A ) chemical structures of <t>CMC2.14,</t> <t>CMC2.24,</t> CMC2.23 and CMC2.5, the red circles show the substituent groups which differ between the CMCs; human keratinocyte (HaCaT) viability in the presence of different concentrations of ( B ) CMC2.14, ( C ) CMC2.24, ( D ) CMC2.23 and ( E ) CMC2.5 measured by MTS assay; (* p < 0.05; ** p < 0.01; *** p < 0.001; # p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test); ( F ) inhibition of phagocytosis of FluoSphere beads by HaCaT cells after 24 h exposure to CMC2.14 (10 µM), CMC2.24 (20 µM), CMC2.23 (20 µM) and CMC2.5 (20 µM); (*** p < 0.001 vs. control; One-way ANOVA with Dunnett’s post hoc test); ( G ) adrenomedullin protein levels in cultures of HaCaT cells treated with the compounds for 48 h (** p < 0.01 and *** p < 0.001 vs. Ctrl; One-way ANOVA with Tukey’s post hoc test) and ( H ) endothelin-1 protein levels in cultures of HaCaT cells treated with compounds. (*** p < 0.001 vs. (−)IL-1β; # p < 0.0001 vs. (+)IL-1β; letter c- p < 0.05 vs. CMC2.5; letter b- p < 0.05 vs. CMC2.5; letter a- p < 0.001 vs. CMC2.14; One-way ANOVA with Tukey’s post hoc test); all data are mean ± SD of triplicates.

Cmc2.23, supplied by ChemMaster International, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/cmc2.23/product/ChemMaster International
Average 90 stars, based on 1 article reviews

cmc2.23 - by Bioz Stars, 2026-06

90/100 stars

Images

1) Product Images from "Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes"

Article Title: Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes

Journal: International Journal of Molecular Sciences

doi: 10.3390/ijms22116043

( A ) chemical structures of CMC2.14, CMC2.24, CMC2.23 and CMC2.5, the red circles show the substituent groups which differ between the CMCs; human keratinocyte (HaCaT) viability in the presence of different concentrations of ( B ) CMC2.14, ( C ) CMC2.24, ( D ) CMC2.23 and ( E ) CMC2.5 measured by MTS assay; (* p < 0.05; ** p < 0.01; *** p < 0.001; # p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test); ( F ) inhibition of phagocytosis of FluoSphere beads by HaCaT cells after 24 h exposure to CMC2.14 (10 µM), CMC2.24 (20 µM), CMC2.23 (20 µM) and CMC2.5 (20 µM); (*** p < 0.001 vs. control; One-way ANOVA with Dunnett’s post hoc test); ( G ) adrenomedullin protein levels in cultures of HaCaT cells treated with the compounds for 48 h (** p < 0.01 and *** p < 0.001 vs. Ctrl; One-way ANOVA with Tukey’s post hoc test) and ( H ) endothelin-1 protein levels in cultures of HaCaT cells treated with compounds. (*** p < 0.001 vs. (−)IL-1β; # p < 0.0001 vs. (+)IL-1β; letter c- p < 0.05 vs. CMC2.5; letter b- p < 0.05 vs. CMC2.5; letter a- p < 0.001 vs. CMC2.14; One-way ANOVA with Tukey’s post hoc test); all data are mean ± SD of triplicates.

Figure Legend Snippet: ( A ) chemical structures of CMC2.14, CMC2.24, CMC2.23 and CMC2.5, the red circles show the substituent groups which differ between the CMCs; human keratinocyte (HaCaT) viability in the presence of different concentrations of ( B ) CMC2.14, ( C ) CMC2.24, ( D ) CMC2.23 and ( E ) CMC2.5 measured by MTS assay; (* p < 0.05; ** p < 0.01; *** p < 0.001; # p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test); ( F ) inhibition of phagocytosis of FluoSphere beads by HaCaT cells after 24 h exposure to CMC2.14 (10 µM), CMC2.24 (20 µM), CMC2.23 (20 µM) and CMC2.5 (20 µM); (*** p < 0.001 vs. control; One-way ANOVA with Dunnett’s post hoc test); ( G ) adrenomedullin protein levels in cultures of HaCaT cells treated with the compounds for 48 h (** p < 0.01 and *** p < 0.001 vs. Ctrl; One-way ANOVA with Tukey’s post hoc test) and ( H ) endothelin-1 protein levels in cultures of HaCaT cells treated with compounds. (*** p < 0.001 vs. (−)IL-1β; # p < 0.0001 vs. (+)IL-1β; letter c- p < 0.05 vs. CMC2.5; letter b- p < 0.05 vs. CMC2.5; letter a- p < 0.001 vs. CMC2.14; One-way ANOVA with Tukey’s post hoc test); all data are mean ± SD of triplicates.

Techniques Used: MTS Assay, Inhibition

Human primary epidermal melanocyte—darkly pigmented (HEMn-DP) viability in the presence of different concentrations of ( A ) CMC2.14; ( B ) CMC2.24; ( C ) CMC2.23; and ( D ) CMC2.5 for 48 h measured by MTS assay (* p < 0.05; # p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). Data are mean ± SD of quadruplicates; melanin content in cultures of HEMn-DP cells treated for 48 h with different concentrations of ( E ) PC and CMC2.24 and ( F ) THC, CMC2.23 and CMC2.5; (*** p < 0.001; # p < 0.0001 vs. control (Ctrl); letter x- p < 0.001 vs. PC-10 µM. One-way ANOVA with Tukey’s test; data are mean ± SD of at least two independent experiments). ( G ) Representative phase-contrast micrographs of HEMn-DP cells treated with 0.16% DMSO (control) and compounds: CMC2.24 (10 µM), CMC2.23 (20 µM) and CMC2.5 (20 µM) at objective magnification 20x; the scale bar shown is 100 microns; quantification of dendricity by ( H ) dendrite number; ( I ) % of cells with >5 dendrites; ( J ) total dendrite length and ( K ) average dendrite length. (* p < 0.05; ** p < 0.01, *** p < 0.001; # p < 0.0001 vs. Ctrl; letter c- p < 0.01 vs. CMC2.5, letter a- p < 0.05 vs. CMC2.23 and letter b- p < 0.001 vs. CMC2.23, one-way ANOVA followed by Tukey’s post hoc test); a total of up to 100 cells were counted from each treatment group and the results shown are mean ± SD of values combined from at least two independent experiments.

Figure Legend Snippet: Human primary epidermal melanocyte—darkly pigmented (HEMn-DP) viability in the presence of different concentrations of ( A ) CMC2.14; ( B ) CMC2.24; ( C ) CMC2.23; and ( D ) CMC2.5 for 48 h measured by MTS assay (* p < 0.05; # p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). Data are mean ± SD of quadruplicates; melanin content in cultures of HEMn-DP cells treated for 48 h with different concentrations of ( E ) PC and CMC2.24 and ( F ) THC, CMC2.23 and CMC2.5; (*** p < 0.001; # p < 0.0001 vs. control (Ctrl); letter x- p < 0.001 vs. PC-10 µM. One-way ANOVA with Tukey’s test; data are mean ± SD of at least two independent experiments). ( G ) Representative phase-contrast micrographs of HEMn-DP cells treated with 0.16% DMSO (control) and compounds: CMC2.24 (10 µM), CMC2.23 (20 µM) and CMC2.5 (20 µM) at objective magnification 20x; the scale bar shown is 100 microns; quantification of dendricity by ( H ) dendrite number; ( I ) % of cells with >5 dendrites; ( J ) total dendrite length and ( K ) average dendrite length. (* p < 0.05; ** p < 0.01, *** p < 0.001; # p < 0.0001 vs. Ctrl; letter c- p < 0.01 vs. CMC2.5, letter a- p < 0.05 vs. CMC2.23 and letter b- p < 0.001 vs. CMC2.23, one-way ANOVA followed by Tukey’s post hoc test); a total of up to 100 cells were counted from each treatment group and the results shown are mean ± SD of values combined from at least two independent experiments.

Techniques Used: MTS Assay

Cellular tyrosinase activity study in HEMn-DP cells treated for 48 h with different concentrations of CMCs; ( A ) CMC2.24; ( B ) CMC2.23; and ( C ) CMC2.5; KA (1 mM) was used as a positive control; (# p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). ( D ) Exposure-recovery study of tyrosinase activity in HEMn-DP cells treated with compounds: CMC2.24 (10 µM) and CMC2.23 (20 µM); letter a- p < 0.01 and letter b- p < 0.01 vs. control at 2 d exposure; letter x- p < 0.05 and letter y- p < 0.05 vs. control at 5 d recovery; unpaired t -test. Levels of TYR and MITF proteins measured in HEMn-DP cells after treatment with various concentrations of ( E ) CMC2.24; ( F ) CMC2.23; and ( G ) CMC2.5; * p < 0.05 and ** p < 0.01 vs. control; human dermal fibroblast viability in the presence of different concentrations of ( H ) PC; ( I ) CMC2.24; ( J ) CMC2.23; and ( K ) CMC2.5 for 48 h measured by MTS assay (# p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). Data for ( A , B ) are representative of one experiment in triplicates out of two separate experiments. Data for ( C ) are mean ± SD of two separate experiments, while all other data are mean ± SD of triplicates.

Figure Legend Snippet: Cellular tyrosinase activity study in HEMn-DP cells treated for 48 h with different concentrations of CMCs; ( A ) CMC2.24; ( B ) CMC2.23; and ( C ) CMC2.5; KA (1 mM) was used as a positive control; (# p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). ( D ) Exposure-recovery study of tyrosinase activity in HEMn-DP cells treated with compounds: CMC2.24 (10 µM) and CMC2.23 (20 µM); letter a- p < 0.01 and letter b- p < 0.01 vs. control at 2 d exposure; letter x- p < 0.05 and letter y- p < 0.05 vs. control at 5 d recovery; unpaired t -test. Levels of TYR and MITF proteins measured in HEMn-DP cells after treatment with various concentrations of ( E ) CMC2.24; ( F ) CMC2.23; and ( G ) CMC2.5; * p < 0.05 and ** p < 0.01 vs. control; human dermal fibroblast viability in the presence of different concentrations of ( H ) PC; ( I ) CMC2.24; ( J ) CMC2.23; and ( K ) CMC2.5 for 48 h measured by MTS assay (# p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). Data for ( A , B ) are representative of one experiment in triplicates out of two separate experiments. Data for ( C ) are mean ± SD of two separate experiments, while all other data are mean ± SD of triplicates.

Techniques Used: Activity Assay, Positive Control, MTS Assay

Image Search Results

Journal: International Journal of Molecular Sciences

Article Title: Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes

doi: 10.3390/ijms22116043

Figure Lengend Snippet: ( A ) chemical structures of CMC2.14, CMC2.24, CMC2.23 and CMC2.5, the red circles show the substituent groups which differ between the CMCs; human keratinocyte (HaCaT) viability in the presence of different concentrations of ( B ) CMC2.14, ( C ) CMC2.24, ( D ) CMC2.23 and ( E ) CMC2.5 measured by MTS assay; (* p < 0.05; ** p < 0.01; *** p < 0.001; # p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test); ( F ) inhibition of phagocytosis of FluoSphere beads by HaCaT cells after 24 h exposure to CMC2.14 (10 µM), CMC2.24 (20 µM), CMC2.23 (20 µM) and CMC2.5 (20 µM); (*** p < 0.001 vs. control; One-way ANOVA with Dunnett’s post hoc test); ( G ) adrenomedullin protein levels in cultures of HaCaT cells treated with the compounds for 48 h (** p < 0.01 and *** p < 0.001 vs. Ctrl; One-way ANOVA with Tukey’s post hoc test) and ( H ) endothelin-1 protein levels in cultures of HaCaT cells treated with compounds. (*** p < 0.001 vs. (−)IL-1β; # p < 0.0001 vs. (+)IL-1β; letter c- p < 0.05 vs. CMC2.5; letter b- p < 0.05 vs. CMC2.5; letter a- p < 0.001 vs. CMC2.14; One-way ANOVA with Tukey’s post hoc test); all data are mean ± SD of triplicates.

Article Snippet: The chemically synthesized curcumin derivatives: CMC2.14, CMC2.24, CMC2.23 and CMC2.5 (all 97% purity) were obtained from ChemMaster Int. (Hauppauge, NY, USA).

Techniques: MTS Assay, Inhibition

Journal: International Journal of Molecular Sciences

Article Title: Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes

doi: 10.3390/ijms22116043

Figure Lengend Snippet: Human primary epidermal melanocyte—darkly pigmented (HEMn-DP) viability in the presence of different concentrations of ( A ) CMC2.14; ( B ) CMC2.24; ( C ) CMC2.23; and ( D ) CMC2.5 for 48 h measured by MTS assay (* p < 0.05; # p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). Data are mean ± SD of quadruplicates; melanin content in cultures of HEMn-DP cells treated for 48 h with different concentrations of ( E ) PC and CMC2.24 and ( F ) THC, CMC2.23 and CMC2.5; (*** p < 0.001; # p < 0.0001 vs. control (Ctrl); letter x- p < 0.001 vs. PC-10 µM. One-way ANOVA with Tukey’s test; data are mean ± SD of at least two independent experiments). ( G ) Representative phase-contrast micrographs of HEMn-DP cells treated with 0.16% DMSO (control) and compounds: CMC2.24 (10 µM), CMC2.23 (20 µM) and CMC2.5 (20 µM) at objective magnification 20x; the scale bar shown is 100 microns; quantification of dendricity by ( H ) dendrite number; ( I ) % of cells with >5 dendrites; ( J ) total dendrite length and ( K ) average dendrite length. (* p < 0.05; ** p < 0.01, *** p < 0.001; # p < 0.0001 vs. Ctrl; letter c- p < 0.01 vs. CMC2.5, letter a- p < 0.05 vs. CMC2.23 and letter b- p < 0.001 vs. CMC2.23, one-way ANOVA followed by Tukey’s post hoc test); a total of up to 100 cells were counted from each treatment group and the results shown are mean ± SD of values combined from at least two independent experiments.

Article Snippet: The chemically synthesized curcumin derivatives: CMC2.14, CMC2.24, CMC2.23 and CMC2.5 (all 97% purity) were obtained from ChemMaster Int. (Hauppauge, NY, USA).

Techniques: MTS Assay

Journal: International Journal of Molecular Sciences

Article Title: Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes

doi: 10.3390/ijms22116043

Figure Lengend Snippet: Cellular tyrosinase activity study in HEMn-DP cells treated for 48 h with different concentrations of CMCs; ( A ) CMC2.24; ( B ) CMC2.23; and ( C ) CMC2.5; KA (1 mM) was used as a positive control; (# p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). ( D ) Exposure-recovery study of tyrosinase activity in HEMn-DP cells treated with compounds: CMC2.24 (10 µM) and CMC2.23 (20 µM); letter a- p < 0.01 and letter b- p < 0.01 vs. control at 2 d exposure; letter x- p < 0.05 and letter y- p < 0.05 vs. control at 5 d recovery; unpaired t -test. Levels of TYR and MITF proteins measured in HEMn-DP cells after treatment with various concentrations of ( E ) CMC2.24; ( F ) CMC2.23; and ( G ) CMC2.5; * p < 0.05 and ** p < 0.01 vs. control; human dermal fibroblast viability in the presence of different concentrations of ( H ) PC; ( I ) CMC2.24; ( J ) CMC2.23; and ( K ) CMC2.5 for 48 h measured by MTS assay (# p < 0.0001 vs. control. One-way ANOVA with Dunnett’s test). Data for ( A , B ) are representative of one experiment in triplicates out of two separate experiments. Data for ( C ) are mean ± SD of two separate experiments, while all other data are mean ± SD of triplicates.

Article Snippet: The chemically synthesized curcumin derivatives: CMC2.14, CMC2.24, CMC2.23 and CMC2.5 (all 97% purity) were obtained from ChemMaster Int. (Hauppauge, NY, USA).

Techniques: Activity Assay, Positive Control, MTS Assay

Review

Structured Review

Images

1) Product Images from "Novel Chemically Modified Curcumin (CMC) Analogs Exhibit Anti-Melanogenic Activity in Primary Human Melanocytes"

Similar Products

Image Search Results